Resolian, the CRO formerly known as Alliance, makes move into China with Denali acquisition

Preview

来源: FierceBiotech

Resolian (formerly Alliance Pharma) continues to expand with the acquisition of bioanalytical CRO Denali Medpharma for an undisclosed price.

Resolian, which changed its name from Alliance Pharma earlier this year, has expanded its services with the acquisition of China-based bioanalytical CRO Denali Medpharma for an undisclosed price.

With the deal, Pennsylvania-based Resolian can claim bioanalysis labs in the U.S., U.K., Australia and China. Denali, which has 70 employees, is known for its work in the bioanalysis of oligonucleotide drugs and mRNA vaccines as well as liposomal drugs, ultra-sensitive assays for inhalation drugs and biomarker assays, Resolian said in a Nov. 1 press release.

“The strategic addition of Denali will significantly enhance our capabilities and strengthen our position in the global market,” Resolian CEO Patrick Bennett said in the release. Financial details of the acquisition weren’t disclosed.

The rebrand to Resolian came in May as part of the company’s integration of U.K.-based CRO Drug Development Solutions, which it acquired last year.

In late 2022, the CRO opened a new lab in Brisbane, Australia, to support preclinical and clinical testing. The 20,000-square-foot facility provides small- and large-molecule bioanalytical services.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。